News releases from Abeona Therapeutics Inc

Abeona Therapeutics Enrolls First Two Patients in Pivotal Expansion of Phase 1/2 Clinical Trial in MPS IIIA

October 11, 2017

Abeona Therapeutics Inc. (Nasdaq:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel gene therapies for life-threatening rare diseases, announced today that two...

Abeona Announces Top-Line One Year Data from ABO-102 MPS IIIA Trial at ARM’s Cell & Gene Meeting on the Mesa

October 06, 2017

Abeona Therapeutics Inc. (NASDAQ:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel gene and cell therapies for life-threatening rare diseases, announced one year...

Abeona Therapeutics Announces Dedication of Commercial Gene Therapy Manufacturing Facility in Cleveland, Ohio

October 04, 2017

Abeona Therapeutics Inc. (Nasdaq:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel gene and cell therapies for life-threatening rare diseases, announced today the...

Abeona Therapeutics and Brammer Bio Announce Collaboration for Commercial Translation of ABO-102

September 28, 2017

Abeona Therapeutics Inc. (Nasdaq:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel gene and cell therapies for life-threatening rare diseases, announced today an...

Abeona Therapeutics Announces Upcoming Conference Participation

September 22, 2017

Abeona Therapeutics Inc. (NASDAQ:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel gene therapies for life-threatening rare genetic diseases, today announced the...

Abeona Therapeutics Receives FDA Breakthrough Therapy Designation for EB-101 Autologous Cell Therapy in Epidermolysis Bullosa

August 29, 2017

Abeona Therapeutics Inc. (Nasdaq:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel gene therapies for life-threatening rare diseases, announced today that the U.S....

Abeona Therapeutics to Host Gene Therapy R&D Day on October 11, 2017

August 17, 2017

Abeona Therapeutics Inc. (Nasdaq:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel gene therapies for life-threatening rare diseases, today announced it will host...

Abeona Therapeutics Reports Second Quarter 2017 Financial Results and Recent Business Highlights

August 15, 2017

Investor Conference Call to be held Tuesday, August 22nd at 10:00 am ET

Abeona Therapeutics Announces Appointment of Juan Ruiz as Chief Medical Officer

July 25, 2017

Abeona Therapeutics Inc. (Nasdaq:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel gene therapies for life-threatening rare diseases, announced today that Juan Ruiz,...

Abeona Therapeutics Receives Guidance from FDA to Commence Pivotal Phase 3 for EB-101 Gene Therapy for Patients with Epidermolysis Bullosa

July 18, 2017

Abeona Therapeutics Inc. (Nasdaq:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel gene therapies for life-threatening rare diseases, announced today guidance from a...

Abeona Therapeutics Receives FDA Orphan Drug Designation for ABO-201 Juvenile Batten Disease Gene Therapy Program

June 29, 2017

Abeona’s Fourth Gene Therapy Program to Receive FDA Orphan Drug Designation

Abeona Therapeutics to Present at the Jefferies 2017 Global Healthcare Conference

June 02, 2017

Company CEO to Present on Wednesday, June 7th at 3:30 PM ET

Abeona Therapeutics Receives Rare Pediatric Disease Designation for EB-101 Gene Therapy Product for Patients with Epidermolysis Bullosa

May 30, 2017

Abeona’s Third Gene Therapy Program to Receive Rare Pediatric Disease Designation, expected to enable Priority Review Voucher

Abeona Therapeutics Receives FDA Orphan Drug Designation for EB-101 Gene Therapy Product for Patients with Epidermolysis Bullosa

May 25, 2017

Abeona Therapeutics Inc. (Nasdaq:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel gene therapies for life-threatening rare diseases, announced today that the FDA...

Abeona Therapeutics to Present at Multiple Upcoming Conferences

May 19, 2017

Abeona Therapeutics Inc. (NASDAQ:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel gene therapies for life-threatening rare diseases, announced that members of the...

Abeona Therapeutics Reports First Quarter 2017 Financial Results and Recent Business Highlights

May 16, 2017

Abeona Therapeutics Inc. (NASDAQ:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel gene therapies for life-threatening rare diseases, announced financial results for...

Abeona Therapeutics Announces Top-Line Data for ABO-102 Phase 1/2 MPS IIIA Gene Therapy Trial at ASGCT

May 12, 2017

Abeona Therapeutics Inc. (NASDAQ:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel gene therapies for life-threatening rare diseases, announced updated data from the...

Abeona Therapeutics Receives Regulatory Approval to Initiate Clinical Trial in Australia with ABO-102 Gene Therapy For Patients with MPS IIIA

May 09, 2017

Clinical Trial Notification (CTN) Enables Initiation at 3rd Global Site and Accelerates Enrollment in the ABO-102 MPS IIIA Gene Therapy Program

Abeona Therapeutics Announces Gene Therapy Clinical Trial and Preclinical Program Presentations at ASGCT 20th Annual Meeting

May 08, 2017

Company to Host Live Conference Call Briefing on Friday, May 12th at 10:00am EDT

Abeona Therapeutics Provides Update on EB-101 Gene Therapy for Severe Form of Epidermolysis Bullosa from the Society for Investigative Dermatology Conference

May 02, 2017

Abeona Therapeutics Inc. (NASDAQ:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel gene therapies for life-threatening rare diseases, announces updated clinical data...

Abeona Therapeutics Announces EB-101 Clinical Update to be Presented at the Society for Investigative Dermatology Annual Meeting

April 25, 2017

Oral Presentation and Poster Sessions Highlighting EB-101 Gene Therapy Clinical Trial Updates and Natural History Study Data for Patients with Recessive Dystrophic Epidermolysis Bullosa (RDEB)

Abeona to Present At Multiple Upcoming Conferences

April 20, 2017

Abeona Therapeutics Inc. (NASDAQ:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel gene therapies for life-threatening rare genetic diseases, today announced...

Abeona Announces Rare Disease Gene Therapy Symposium with the New York Academy of Sciences

April 05, 2017

Abeona Therapeutics Inc. (NASDAQ:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel gene therapies for life-threatening rare genetic diseases, is pleased to announce...

Abeona Therapeutics Reports Q4 2016 Financial Results and Business Highlights

March 31, 2017

Management to Host Investor Conference Call on Monday, April 10th at 10:00 am ET to Provide Progress Report on Corporate Developments

Abeona Therapeutics to Present at Multiple Upcoming Investor Conferences

March 13, 2017

Company COO to Present on Tuesday, March 14th & Tuesday, March 21st

Abeona Therapeutics Receives Orphan Drug Designation in the European Union for EB-101 Gene Therapy Clinical Trial for Epidermolysis Bullosa

March 08, 2017

Abeona Therapeutics Inc. (Nasdaq:ABEO), a leading clinical-stage biopharmaceutical company focused on developing gene therapies for life-threatening rare diseases, announced today that the European...

Abeona Therapeutics To Present At The Cowen and Company 37th Annual Health Care Conference

March 06, 2017

Company COO to Present on Wednesday, March 8th at 9:20 AM EST

Abeona Therapeutics to Present at Maxim Group LLC Biotech Investor & Partnering Conference in Shanghai

March 02, 2017

Company CEO to Present on Monday, March 6th at 11:45 am CST

Abeona Therapeutics Announces Dismissal of Securities Class Action Lawsuit

February 22, 2017

Abeona Therapeutics Inc. (Nasdaq:ABEO), a leading clinical-stage biopharmaceutical company focused on developing therapies for life-threatening rare genetic diseases, announced today that on February...

Abeona Therapeutics to Present at the 2017 RBC Capital Markets Global Healthcare Conference and 3rd Annual CRISPR Congress

February 20, 2017

Abeona Therapeutics Inc. (NASDAQ:ABEO) a leading clinical-stage biopharmaceutical company focused on developing therapies for life-threatening rare genetic diseases, today announced that members of...

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.